Emergen Research has announced the launch of its advanced Targeted DNA RNA Sequencing market research content, designed to provide businesses with valuable insights and strategic direction in an increasingly competitive marketplace. As industries continue to evolve rapidly, organizations must rely on accurate and up-to-date information to stay ahead. This comprehensive research content helps businesses understand market trends, consumer behavior, and emerging opportunities, enabling them to make well-informed decisions.
One of the most important aspects of this offering is its ability to deliver expert insights that go beyond basic data analysis. The Targeted DNA RNA Sequencing market research content is developed by experienced analysts who bring deep industry knowledge and a strong understanding of market dynamics. Their expertise allows businesses to gain clarity on complex trends and prepare for future challenges with confidence.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-free-sample/4627
By Product Outlook (Revenue, USD Billion; 2020-2035)Â
- NGS
- Method
- Exome Sequencing
- Enrichment Sequencing
- Amplicon Sequencing
- Others
- Application
- Cancer Gene Sequencing
- Inherited Disease Screening
- Drug Development
- Forensic Genomics
- 16S ribosomal RNA (rRNA) sequencing
- Others
- Method
By Workflow Outlook (Revenue, USD Billion; 2020-2035)Â
- Pre-sequencing
- Sequencing
- Data Analysis
By Application Outlook (Revenue, USD Billion; 2020-2035)Â
- Human Biomedical Research
- Plant & Animal Sciences
- Drug Discovery
- Others
By Type Outlook (Revenue, USD Billion; 2020-2035)Â
- DNA Based Targeted Sequencing
- RNA Based Targeted Sequencing
By End-use Outlook (Revenue, USD Billion; 2020-2035)Â
- Academic Research
- Hospitals & Clinics
- Pharma & Biotech Entities
- Others
By Regional Outlook (Revenue, USD Billion; 2020-2035)Â
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Benelux
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East and Africa
- Saudi Arabia
- UAE
- South Africa
- Turkey
- Rest of MEA
In addition to expert analysis, the report emphasizes the importance of actionable recommendations. Businesses are not only provided with data but also with practical guidance that can be implemented to improve performance. These insights help organizations enhance their products, optimize their services, and create better customer experiences, ultimately driving growth and profitability.
The research also highlights the importance of staying updated in a constantly changing business environment. Markets are influenced by technological advancements, economic conditions, and shifting consumer preferences. Emergen Research ensures that its content is regularly updated, enabling businesses to adapt quickly and maintain their competitive edge.
The Targeted DNA RNA Sequencing Market is expected to grow from an estimated USD 11.3 billion in 2024 to USD 59.2 billion in 2035, at a CAGR of 20.20%.
Government-sponsored initiatives and organisational programs are critical factors driving the Targeted DNA and RNA Sequencing Market. Agencies such as the National Institutes of Health (NIH) and the National Institute of Environmental Health Sciences (NIEHS) have helped cultivate research and innovation.
The NIH’s National Human Genome Research Institute (NHGRI), for instance, has invested heavily in refining sequencing technologies to improve diagnostic resolution and decrease costs. Such programmes are not only advancing the field but are also creating accessible healthcare solutions through genomic medicine.
In 2024, NIEHS and NHGRI co-hosted a workshop on RNA sequencing technologies with an emphasis on epi transcriptomics, which promises insight into complex diseases such as cancer and neurodegenerative disorders.
Government reports also reveal that targeted approaches, including the Twist Viral Research Panel, were 10–100× more sensitive than untargeted sequencing and had lower total costs for smaller sample sizes. In particular, sequencing a batch of 23 samples with the Twist panel is less expensive than the untargeted Illumina approach and, thus, easier to generalise.
However, the reliance on government-supported frameworks is increasing. It is reported that NIH-funded sequencing projects increased diagnostic yields for rare diseases by 35% in 2023, and the adoption of targeted sequencing reduced average costs of sequencing by up to 40%. These achievements indicate the importance of institutional support in propelling technological innovation and making markets more accessible.
The Targeted DNA RNA Sequencing market research content includes a wide variety of materials such as in-depth reports, whitepapers, case studies, and trend analyses. These resources are designed to provide a holistic view of the market and are applicable across multiple industries including technology, healthcare, finance, consumer goods, and manufacturing. This wide coverage ensures that businesses from different sectors can benefit from the insights provided.
Market Segmentation:
Another key component of the report is its detailed market segmentation analysis. By examining the Targeted DNA RNA Sequencing market across different product types, applications, and end-user industries, the study offers a clear understanding of demand patterns and growth opportunities. This segmentation helps organizations identify the most promising areas and allocate their resources more effectively.
The outlook for the Targeted DNA and RNA Sequencing Market remains positive due to significant government funding and progress in sequencing technologies, especially in cancer research and inherited disease screening. Asia-Pacific is the fastest-growing region, with increased government support fueling market expansion.
In terms of competitive analysis, leading companies such as Illumina, Thermo Fisher Scientific, and Pacific Biosciences are driving market innovation, supported by government partnerships and research programs, strengthening their market positions.
In June 2024, Bio-Rad launched the ddSEQ Single-Cell 3′ RNA-Seq Kit, designed to support single-cell gene expression research. This kit allows researchers to efficiently and affordably analyse gene expression at the single-cell level, potentially advancing research in oncology, immunology, and other fields.
Some of the key companies in the global Targeted DNA RNA Sequencing market include:
- Illumina
- F. Hoffman-La Roche Ltd.
- QIAGEN
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- Oxford Nanopore Technologies
- PierianDx
- Genomatix GmbH
- DNASTAR, Inc.
- Perkin Elmer, Inc.
Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/4627
Competitive Landscape:
Understanding the competitive landscape is essential for any business aiming to succeed in today’s market. The report provides an in-depth analysis of key market players, highlighting their company profiles, strategies, and recent developments. It examines activities such as mergers and acquisitions, collaborations, joint ventures, and technological advancements, offering valuable insights into how competitors are evolving.
Increasing Government Investments in Genomic Research Infrastructure Boost the Market Growth
Government investments in genomics research infrastructure greatly advance the Targeted DNA and RNA Sequencing Market. The Horizon Europe program, set up by the European Union, invested billions of euros to fuel genomics into further advancements for precision medicine and public health initiatives.
In the United States, the NIH’s All of Us Research Program focuses on sequencing more than one million people’s genomes; it has focused on targeted sequencing to identify genetic tendencies toward diseases. Such megaprojects are also encouraging the use of inexpensive and highly sensitive sequencing technologies.
Government-funded projects are showing impressive increases in the efficiency of research. NIH data show that the sequencing technologies funded by their initiatives have brought down the cost of sequencing from over $10 million per genome in 2006 to less than $1,000 by 2024.
Similarly, targeted RNA sequencing initiatives funded by the NIEHS have improved diagnostic accuracy for rare diseases by 45% over untargeted methods. This shows how infrastructure and funding from governments are addressing both affordability and accessibility in the market.
Emergen Research’s primary objective is to empower businesses with the knowledge they need to thrive. The research content is designed to provide comprehensive analysis and a competitive advantage, helping organizations identify untapped opportunities and develop effective strategies.
The Targeted DNA RNA Sequencing market research content is useful for a wide range of stakeholders. It serves as a valuable resource for key market players, investors, venture capitalists, and enterprises of all sizes. Additionally, third-party knowledge providers, value-added resellers, producers, distributors, and suppliers can use the insights to improve their operations. Research organizations, consulting firms, and policymakers also benefit from the detailed analysis provided in the report.
Another major strength of the research is its comprehensive approach. Each report offers a detailed examination of market trends, consumer behavior, and competitive dynamics. This allows businesses to gain a complete understanding of the market and make data-driven decisions that support long-term growth.
Furthermore, the inclusion of timely updates ensures that the content remains relevant in a rapidly changing environment. Businesses can rely on Emergen Research to provide accurate and current information, enabling them to adapt their strategies as needed.
Browse Full Report Description + Research Methodology + Table of Content + Infographics @ https://www.emergenresearch.com/industry-report/targeted-dna-rna-sequencing-market
About Emergen Research
Emergen Research is a leading market research and consulting company that provides syndicated research reports, customized research solutions, and consulting services. The company focuses on helping clients analyze consumer behavior, identify market trends, and make informed decisions across multiple industries.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: https://www.emergenresearch.com/
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com